Lacritin cleavage-potentiated targeting of iron - respiratory reciprocity promotes bacterial death

Mohammad Sharifian Gh1, Fatemeh Norouzi1, Mirco Sorci2

  • 1Department of Cell Biology, University of Virginia, Charlottesville, Virginia, USA.

Insights

A novel antibacterial peptide, N-104, derived from lacritin, inhibits bacterial respiration by targeting multiple transporters. This discovery offers a new antibiotic strategy against critical pathogens like Pseudomonas aeruginosa.

Area of Science:

  • Microbiology
  • Bacteriology
  • Drug Discovery

Background:

  • Current antibiotics target established pathways; novel strategies are needed.
  • Targeting bacterial transporters to inhibit respiration is a long-standing goal.
  • Lacritin, a secreted mitogen, has a previously unrecognized antibacterial role.

Purpose of the Study:

  • To identify and characterize a novel bacterial transporter inhibitor.
  • To elucidate the mechanism of action of the antibacterial peptide N-104.
  • To evaluate N-104 as a potential therapeutic agent against critical bacterial pathogens.

Main Methods:

  • Identification of N-104 as a lacritin cleavage fragment with bactericidal activity.
  • Surface plasmon resonance and SYTOX Orange entry assays to determine nonlytic mechanism.
  • Unbiased genetic screen in Escherichia coli to identify N-104 resistance mechanisms.
  • Validation in Pseudomonas aeruginosa PA14, targeting YaiW, FeoB, and PotH transporters.
  • Analysis of gene expression changes related to aerobic and anaerobic respiration.

Main Results:

  • N-104, a fragment of lacritin, exhibits potent bactericidal activity.
  • The nonlytic mechanism involves sequential inhibition of bacterial transporters FeoB and PotH.
  • N-104 induces a lethal suppression of bacterial respiration, favoring anaerobic pathways.
  • Polypharmacology of N-104 revealed through extensive genetic screening.
  • Synergistic activity observed with tear thrombin fragment GKY20 against resistant isolates.

Conclusions:

  • N-104 represents a novel class of antibacterial agents targeting bacterial respiration.
  • The multi-transporter inhibition mechanism offers a strategy to overcome resistance.
  • Lacritin and its derivatives hold promise for developing new antibiotic therapies, particularly for eye infections.